Latest stories on OTLK
Outlook Therapeutics Resubmits FDA Application for ONS-5010
TipRanks58 · neutralproduct/pr
Outlook Therapeutics Announces Insider-Backed Direct Stock Offering
TipRanks53 · neutralgeneral
Outlook Therapeutics prices $5M registered direct offering
Seeking Alpha34 · bearishgeneral
FDA Appeal Win Clears Path for Outlook Therapeutics' ONS-5010/LYTENAVA to Resubmit for Approval
MarketChameleon77 · bullishproduct/pr
Outlook Therapeutics Wins FDA Appeal for LYTENAVA Resubmission
TipRanks77 · bullishproduct/pr
Outlook Therapeutics Non-GAAP EPS of -$0.16 misses by $0.04, revenue of $0.13M misses by $4.27M
Seeking Alpha33 · bearishearnings